Invasive pulmonary aspergillosis, part 2: Treatment Journal Article

  


Authors: Papanicolaou, G. A.; White, D. A.
Article Title: Invasive pulmonary aspergillosis, part 2: Treatment
Abstract: In general, the management of invasive pulmonary aspergillosis is based on antifungal therapy and reversal of immunosuppression. Voriconazole is the preferred treatment in most cases. Liposomal preparations of amphotericin B, caspofungin, and posaconazole are alternatives in patients who cannot tolerate voriconazole or have refractory aspergillosis. Prophylaxis in high-risk patients has gained popularity with the availability of oral extended-spectrum azoles; posaconazole is approved for prophylaxis in patients with acute leukemia, myelodysplastic syndrome, and graft versus host disease.
Keywords: neutropenia; drug dose reduction; unindexed drug; transplantation; high risk patient; acute leukemia; myelodysplastic syndrome; warfarin; graft versus host reaction; benzodiazepine derivative; vinca alkaloid; infection prevention; drug dose increase; tacrolimus; rifampicin; calcium channel blocking agent; hydroxymethylglutaryl coenzyme a reductase inhibitor; sulfonylurea derivative; rapamycin; caspofungin; cyclosporin; posaconazole; voriconazole; aspergillosis; lung aspergillosis; phenytoin; omeprazole; carbamazepine; itraconazole; pimozide; rifabutin; anticoagulant agent; long acting drug; ergot alkaloid; amphotericin b lipid complex; antifungal therapy; quinidine; hematological malignancy; anidulafungin; astemizole; barbituric acid derivative; cisapride; coumarin derivative
Journal Title: Journal of Respiratory Diseases
Volume: 29
Issue: 11
ISSN: 0194-259X
Publisher: Cliggott  
Date Published: 2008-11-01
Start Page: 429
End Page: 434
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-76749161367&partnerID=40&md5=58a73bd7d8430d80c6e652307dbee0e7
Notes: --- - "Export Date: 17 November 2011" - "CODEN: JRDIF" - "Source: Scopus"